Allogene Therapeutics, Inc.
NASDAQAllogene Therapeutics enters September with an unusual structural tension: Pfizer holds a 13D activist stake in the company while short sellers remain deeply dug in at more than a quarter of the free float. The short side of the ledger is hard to ignore. Short interest is running at 26.3% of the free float — one of the highest readings in the clinical-stage cell therapy space — and…
ALLO short interest surges 26% in one week to 28.2% of float, highest level in months amid biotech selloff.
Snapshot as of 26 Sept 2026
Allogene Therapeutics enters September with an unusual structural tension: Pfizer holds a 13D activist stake in the company while short sellers remain deeply dug in at more than a quarter of the free float. The short…
Allogene Therapeutics enters the back half of July with a striking contradiction at its core: short sellers are piling in aggressively even as the Street maintains a bullish consensus on the company's Phase 3 cema-cel…
ALLO just delivered its Q1 2026 results, and the headline number came in better than feared. EPS landed at -$0.18, a penny ahead of the -$0.19 consensus. The stock is up about 6% on the week at $2.30. Yet short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALLO — free to start on ORTEX.
Sign up for free →Open ALLO on ORTEX